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Purpose of the study
To investigate the levels of resistance and therefore the
number of available drugs in heavily pretreated HIV-1
patients in Greece.
Methods
The number of available drugs was estimated in 140
patients who had undergone >6 treatment failures (HIV-
RNA>1000 copies/mL) by using the Rega V7.1.1 algo-
rithm based on the results of the genotypic resistance test-
ing.
Summary of results
Among 140 heavily experienced patients, the number of
available drugs were as shown in Table 1.
Inclusion of darunavir and etravirine significantly
increased the percentage of patients having at least one
fully-active drug from two or three different drug catego-
ries. Specifically, this percentage changed from 21% to
44% (two categories) and from 15% to 31% (three cate-
gories) (p < 0.001). Interestingly, in the study population,
81 (58%) individuals had no options in the N(t)RTI class.
Concerning the other drug classes, 33 (41%) individuals
had no available NNRTIs, while 58 (72%) of them had
less than two options among the PIs.
Conclusion
Despite the approval of new active drugs (DRV, ETV), for
a considerable percentage of heavily pretreated patients
there are not any fully active drugs available among the
N(t)RTIs which comprise the backbone of HAART.
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0–1 87 (62.1%) 77 (55%) 0 48 (34.3%)
2–4 27 (19.3%) 15 (10.7%) 1 42 (30%)
>4 26 (18.6%) 48 (34.3%) ≥ 2 50 (35.7%)
